The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH ...

The U.S. FDA granted Orphan Drug Designation to Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treating endogenous Cushing's syndrome, a rare endocrine disorder with high unmet medical need.

This Wire brief sits within Fusion42's coverage of Biotech.